Cartesian Therapeutics, Inc. (RNAC) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 20.55M USD | Liabilities, Current |
| Cash and equivalents | 147.61M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 196.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $20.55M | $147.61M | (m) | $196.00K | (m) | (m) |
| 2026-03-31 | (m) | $15.95M | $118.64M | (m) | $261.00K | (m) | (m) |
| 2025-12-31 | (m) | $14.94M | $125.14M | (m) | $1.11M | (m) | (m) |
| 2025-09-30 | (m) | $13.80M | $143.38M | (m) | $722.00K | (m) | (m) |
| 2025-06-30 | (m) | $12.26M | $160.32M | (m) | $354.00K | (m) | (m) |
| 2025-03-31 | (m) | $15.00M | $180.43M | (m) | $1.76M | (m) | (m) |
| 2024-12-31 | (m) | $22.98M | $212.61M | (m) | $872.00K | (m) | (m) |
| 2024-09-30 | (m) | $21.41M | $219.20M | (m) | $4.83M | (m) | (m) |
| 2024-06-30 | (m) | $26.11M | $87.23M | (m) | $32.04M | (m) | (m) |
| 2024-03-31 | (m) | $36.65M | $103.42M | (m) | $2.01M | (m) | (m) |
| 2023-12-31 | $82.78M | $68.21M | $76.91M | $0.00 | $5.87M | (m) | 1.21× |
| 2023-09-30 | $84.50M | $19.94M | $79.60M | $0.00 | $4.90M | (m) | 4.24× |
| 2023-06-30 | $117.41M | $29.37M | $112.03M | $0.00 | $5.38M | (m) | 4.00× |
| 2023-03-31 | $132.76M | $26.53M | $125.92M | $0.00 | $6.84M | (m) | 5.00× |
| 2022-12-31 | $141.20M | $25.08M | $106.44M | $28.16M | $6.60M | (m) | 5.63× |
| 2022-09-30 | $153.37M | $23.73M | $112.84M | $33.60M | $6.92M | (m) | 6.46× |
| 2022-06-30 | $166.05M | $33.76M | $138.06M | $4.00M | $23.99M | (m) | 4.92× |
| 2022-03-31 | $124.59M | $39.25M | $113.44M | $4.00M | $7.15M | (m) | 3.17× |
| 2021-12-31 | $137.97M | $72.25M | $114.06M | $14.00M | $9.91M | (m) | 1.91× |
| 2021-09-30 | $145.99M | $95.62M | $114.64M | $24.02M | $7.32M | (m) | 1.53× |
| 2021-06-30 | $158.60M | $87.30M | $125.75M | $24.39M | $8.46M | (m) | 1.82× |
| 2021-03-31 | $156.15M | $84.61M | $125.41M | $22.41M | $8.34M | (m) | 1.85× |
| 2020-12-31 | (m) | $81.55M | $138.69M | (m) | $7.22M | (m) | (m) |
| 2020-09-30 | (m) | $77.00M | $146.26M | (m) | $12.63M | (m) | (m) |
| 2020-06-30 | (m) | $22.51M | $59.73M | (m) | $0.00 | (m) | (m) |
| 2020-03-31 | (m) | $30.07M | $72.61M | (m) | $0.00 | (m) | (m) |
| 2019-12-31 | (m) | $34.94M | $89.89M | (m) | $5.00M | (m) | (m) |
| 2019-09-30 | (m) | $29.48M | $34.23M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $31.91M | $30.20M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $33.05M | $32.17M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $35.14M | $37.40M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $34.63M | $50.48M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $13.89M | $60.24M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $11.81M | $58.23M | (m) | $52.00K | (m) | (m) |
| 2018-01-01 | (m) | $10.97M | (m) | (m) | $63.00K | (m) | (m) |
| 2017-12-31 | (m) | $10.97M | $70.62M | (m) | $63.00K | (m) | (m) |
| 2017-09-30 | (m) | $11.32M | $72.15M | (m) | $0.00 | (m) | (m) |
| 2017-06-30 | (m) | $20.05M | $82.63M | (m) | $1.00K | (m) | (m) |
| 2017-03-31 | (m) | $13.30M | $26.64M | (m) | $63.00K | (m) | (m) |
| 2016-12-31 | (m) | $13.71M | $58.66M | (m) | $215.00K | (m) | (m) |
| 2016-09-30 | (m) | $7.69M | $59.49M | (m) | $483.00K | (m) | (m) |
| 2016-06-30 | (m) | $8.94M | $82.65M | (m) | $1.96M | (m) | (m) |
| 2016-03-31 | (m) | (m) | $17.05M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $7.29M | $32.34M | (m) | $824.00K | (m) | (m) |
| 2015-09-30 | (m) | (m) | $37.51M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $13.15M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $16.59M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $8.06M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |